BDRX Latest Press Releases

-- October 13, 2026 --

Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP Globe Newswire 8:30 AM

-- September 23, 2026 --

The Longview: Fireside Chat with Biodexa CEO Stephen Stamp ACCESS Newswire 6:30 AM

-- September 15, 2026 --

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds Globe Newswire 8:00 AM

-- September 11, 2026 --

Interim results for the six months ended June 30, 2026 Globe Newswire 4:30 PM

-- August 19, 2026 --

Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP Globe Newswire 8:30 AM

-- July 29, 2026 --

Result of General Meeting Globe Newswire 4:30 PM

Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France Globe Newswire 8:30 AM

-- June 30, 2026 --

Result of Annual General Meeting Globe Newswire 4:30 PM

Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants Globe Newswire 8:00 AM

-- June 29, 2026 --

Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress Globe Newswire 8:30 AM

-- June 17, 2026 --

Postponement and Re-scheduling of Annual General Meeting Globe Newswire 4:30 PM

Market Data Delayed 15 Minutes